Abstract

Hypertension is a condition in which blood pressure is elevated to an extent where benefit is obtained from blood pressure lowering. The risk of complications is proportional to the level that blood pressure raises. Calcium channel blockers are a class of compounds used in the treatment of hypertension. The dihydropyridine (DHP) group, a subclass of the calcium channel blocker works almost exclusively on L-type calcium channels in the peripheral arterioles and reduce blood pressure by reducing total peripheral resistant. Long acting DHP is preferred because they are more convenient for patients and avoid the large fluctuations in plasma drug concentration which are associated with side effects. Amlodipine is the most distinct DHP and the most popular. The drug was patented in the year 1986 and its commercial sale began by 1990. The current article provides a state of art about the analytical and bioanalytical techniques available for the quantification of drug as a single entity and in combined pharmaceutical formulations between 1989 and 2019.

摘要

高血压是血压升高到可以从降低血压中获益的程度。并发症的风险与血压升高的水平成正比。钙通道阻滞剂是一类用于治疗高血压的化合物。二氢吡啶 (DHP) 组是钙通道阻滞剂的一个子类，几乎完全作用于外周小动脉中的 L 型钙通道，并通过降低总外周阻力来降低血压。长效 DHP 是首选，因为它们对患者更方便，并且避免了与副作用相关的血浆药物浓度的大波动。氨氯地平是最独特的 DHP，也是最受欢迎的。该药物于 1986 年获得专利，并于 1990 年开始商业销售。